Sarah E Paul1, Alexander S Hatoum2, Deanna M Barch3, Wesley K Thompson4, Arpana Agrawal5, Ryan Bogdan6, Emma C Johnson7. 1. Department of Psychological and Brain Sciences, Washington University in St. Louis, 6411 Forsyth Blvd, St. Louis, MO 63105, USA. Electronic address: spaul24@wustl.edu. 2. Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA. Electronic address: ashatoum@wustl.edu. 3. Department of Psychological and Brain Sciences, Washington University in St. Louis, 6411 Forsyth Blvd, St. Louis, MO 63105, USA; Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA; Department of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, St. Louis, MO 63110, USA. Electronic address: dbarch@wustl.edu. 4. Division of Biostatistics and Department of Radiology, UCSD, La Jolla, CA 92093, USA. Electronic address: wes.stat@gmail.com. 5. Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA. Electronic address: arpana@wustl.edu. 6. Department of Psychological and Brain Sciences, Washington University in St. Louis, 6411 Forsyth Blvd, St. Louis, MO 63105, USA. Electronic address: rbogdan@wustl.edu. 7. Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA. Electronic address: emma.c.johnson@wustl.edu.
Abstract
BACKGROUND: Cognition is robustly associated with substance involvement. This relationship is attributable to multiple factors, including genetics, though such contributions show inconsistent patterns in the literature. For instance, genome-wide association studies point to potential positive relationships between educational achievement and common substance use but negative relationships with heavy and/or problematic substance use. METHODS: We estimated associations between polygenic risk for substance involvement (i.e., alcohol, tobacco, and cannabis use and problematic use) and cognition subfacets (i.e., general ability, executive function, learning/memory) derived from confirmatory factor analysis among 3205 substance naïve children (ages 9-10) of European ancestry who completed the baseline session of the Adolescent Brain Cognitive Development (ABCD) Study. FINDINGS: Polygenic risk for lifetime cannabis use was positively associated with all three facets of cognitive ability (Bs ≥ 0.045, qs ≤ 0.044). No other substance polygenic risk scores showed significant associations with cognition after adjustment for multiple testing (|Bs|≤0.033, qs ≥ 0.118). CONCLUSIONS: Polygenic liability to lifetime cannabis use, but not use disorder, was positively associated with cognitive performance among substance-naïve children, possibly reflecting shared genetic overlap with openness to experience or the influence of genetic variance associated with socioeconomic status. Our lack of findings for the other polygenic scores may reflect ascertainment differences between the genome-wide association study (GWAS) samples and the current sample and/or the young age of the present sample. As longitudinal data in ABCD are collected, this sample may be useful for disentangling putatively causal or predispositional influences of substance use and misuse on cognition.
BACKGROUND: Cognition is robustly associated with substance involvement. This relationship is attributable to multiple factors, including genetics, though such contributions show inconsistent patterns in the literature. For instance, genome-wide association studies point to potential positive relationships between educational achievement and common substance use but negative relationships with heavy and/or problematic substance use. METHODS: We estimated associations between polygenic risk for substance involvement (i.e., alcohol, tobacco, and cannabis use and problematic use) and cognition subfacets (i.e., general ability, executive function, learning/memory) derived from confirmatory factor analysis among 3205 substance naïve children (ages 9-10) of European ancestry who completed the baseline session of the Adolescent Brain Cognitive Development (ABCD) Study. FINDINGS: Polygenic risk for lifetime cannabis use was positively associated with all three facets of cognitive ability (Bs ≥ 0.045, qs ≤ 0.044). No other substance polygenic risk scores showed significant associations with cognition after adjustment for multiple testing (|Bs|≤0.033, qs ≥ 0.118). CONCLUSIONS: Polygenic liability to lifetime cannabis use, but not use disorder, was positively associated with cognitive performance among substance-naïve children, possibly reflecting shared genetic overlap with openness to experience or the influence of genetic variance associated with socioeconomic status. Our lack of findings for the other polygenic scores may reflect ascertainment differences between the genome-wide association study (GWAS) samples and the current sample and/or the young age of the present sample. As longitudinal data in ABCD are collected, this sample may be useful for disentangling putatively causal or predispositional influences of substance use and misuse on cognition.
Authors: Daniel E Gustavson; Michael C Stallings; Robin P Corley; Akira Miyake; John K Hewitt; Naomi P Friedman Journal: J Abnorm Psychol Date: 2017-01-02
Authors: Ryan Bogdan; Arpana Agrawal; Alexander S Hatoum; Emma C Johnson; Sarah M C Colbert; Renato Polimanti; Hang Zhou; Raymond K Walters; Joel Gelernter; Howard J Edenberg Journal: Neuropsychopharmacology Date: 2021-11-08 Impact factor: 8.294
Authors: Atika Khurana; Dan Romer; Laura M Betancourt; Nancy L Brodsky; Joan M Giannetta; Hallam Hurt Journal: Addiction Date: 2012-11-01 Impact factor: 6.526
Authors: Jean-François G Morin; Mohammad H Afzali; Josiane Bourque; Sherry H Stewart; Jean R Séguin; Maeve O'Leary-Barrett; Patricia J Conrod Journal: Am J Psychiatry Date: 2018-10-03 Impact factor: 18.112
Authors: Sandra Weintraub; Sureyya S Dikmen; Robert K Heaton; David S Tulsky; Philip D Zelazo; Patricia J Bauer; Noelle E Carlozzi; Jerry Slotkin; David Blitz; Kathleen Wallner-Allen; Nathan A Fox; Jennifer L Beaumont; Dan Mungas; Cindy J Nowinski; Jennifer Richler; Joanne A Deocampo; Jacob E Anderson; Jennifer J Manly; Beth Borosh; Richard Havlik; Kevin Conway; Emmeline Edwards; Lisa Freund; Jonathan W King; Claudia Moy; Ellen Witt; Richard C Gershon Journal: Neurology Date: 2013-03-12 Impact factor: 9.910
Authors: M Luciana; J M Bjork; B J Nagel; D M Barch; R Gonzalez; S J Nixon; M T Banich Journal: Dev Cogn Neurosci Date: 2018-02-21 Impact factor: 6.464
Authors: Max Lam; Swapnil Awasthi; Hunna J Watson; Jackie Goldstein; Georgia Panagiotaropoulou; Vassily Trubetskoy; Robert Karlsson; Oleksander Frei; Chun-Chieh Fan; Ward De Witte; Nina R Mota; Niamh Mullins; Kim Brügger; S Hong Lee; Naomi R Wray; Nora Skarabis; Hailiang Huang; Benjamin Neale; Mark J Daly; Manuel Mattheisen; Raymond Walters; Stephan Ripke Journal: Bioinformatics Date: 2020-02-01 Impact factor: 6.937
Authors: Nora D Volkow; George F Koob; Robert T Croyle; Diana W Bianchi; Joshua A Gordon; Walter J Koroshetz; Eliseo J Pérez-Stable; William T Riley; Michele H Bloch; Kevin Conway; Bethany G Deeds; Gayathri J Dowling; Steven Grant; Katia D Howlett; John A Matochik; Glen D Morgan; Margaret M Murray; Antonio Noronha; Catherine Y Spong; Eric M Wargo; Kenneth R Warren; Susan R B Weiss Journal: Dev Cogn Neurosci Date: 2017-10-10 Impact factor: 6.464